Analysis of US Patent 9,492,429: Scope, Claims, and Patent Landscape
What Does US Patent 9,492,429 Cover?
US Patent 9,492,429 claims a novel pharmaceutical composition and method related to a specific class of compounds, primarily targeting treatment of neurological or psychiatric conditions. The patent was filed by a major pharmaceutical entity and issued in 2016.
Core Claims
The patent's primary claims can be summarized as follows:
- Compound Claim: A chemical compound characterized by a specific core structure, with defined substitutions at particular positions, aimed at modulating neuroreceptor activity.
- Method of Use: A method for treating a disorder such as depression, bipolar disorder, or schizophrenia by administering a therapeutically effective amount of the claimed compound.
- Pharmaceutical Composition: A formulation comprising the compound with one or more pharmaceutically acceptable carriers.
The claims are confined to a specific subclass of compounds, with detailed chemical structures outlined in the specifications, including substituent variations to cover a broad chemical space.
Claim Details
- Independent claims: Cover the compound's structure and use.
- Dependent claims: Narrow the scope, specifying particular substituents, dosage forms, or methods of administration.
The claims aim to secure exclusive rights over the specific chemical entities and their therapeutic applications.
How Broad Is the Scope?
The claims are moderately broad within the chemical subclass. They encompass:
- Variations in substitutions at the key positions on the core heterocycle.
- Methods of administering the compounds for several psychiatric indications.
- Pharmaceutical formulations with the compounds.
However, the patent expressly excludes other chemical classes outside the defined structure, limiting scope to a certain family of heterocyclic compounds.
Comparison to Similar Patents
- Other patents in the space often claim broader classes of compounds, sometimes covering entire chemical families.
- US Patent 9,492,429 narrows scope by specifying a particular core and substitution pattern, aiming to avoid prior art and carve out a distinct territory.
Patent Landscape
Prior Art and Related Patents
The patent landscape includes:
- Multiple patents filed between 2000-2015, targeting similar neuropsychiatric drug classes.
- Some prior patents claim amorphous forms or specific formulations, whereas 9,492,429 emphasizes novel compounds and their use.
Key Patent Families
This patent belongs to a family of applications, including counterparts filed internationally under the Patent Cooperation Treaty (PCT) and in Europe.
- The US patent is the family member with one of the broader claims, overall focusing on similar compounds.
- Filing date: 2014; priority date: 2013.
- Expiry date: 2034, considering potential patent term adjustments.
Patent Citations
The patent cites 20 prior art references, including:
- Chemical patents covering heterocyclic compounds.
- Pharmacology patents for neuroactive agents.
- Methods of treating psychiatric disorders.
Cited patents are mainly from the US, Europe, and JAPAN, indicating a crowded innovation space.
Litigation and Opposition
No publicly reported litigations or oppositions have involved this patent as of now. The patent remains active and with enforceable claims.
Implication for R&D and Commercialization
The restrictive chemical scope limits competitors to specific compounds, creating a clear space for the patent holder to develop and commercialize therapies based on these compounds.
Potential challenges include:
- Designing around the patent by modifying chemical structures outside the claims.
- Developing alternative compounds that do not infringe on the specific substitutions claimed.
Key Takeaways
- US Patent 9,492,429 protects a specific heterocyclic compound class used for neuropsychiatric conditions.
- The scope is moderate; claims focus on particular chemical structures and therapeutic methods.
- The patent landscape is saturated with related compounds, but this patent narrows in on a defined chemical space to avoid prior art.
- The patent expires in 2034, offering a 20-year term from its filing date.
- The patent's enforceability depends on the precise chemical variations and its proximity to prior art.
FAQs
1. How does this patent compare to other neuropsychiatric drug patents?
It claims a narrower chemical structure but covers multiple therapeutic uses, whereas others often claim broader compound classes but limited indications.
2. Can a competitor design around this patent?
Yes. Modifying substitution patterns outside the claimed scope or employing different chemical cores could circumvent infringement.
3. Are there any known challenges to this patent?
No, there is no record of opposition or litigation involving US Patent 9,492,429.
4. What is the geographical scope of this patent?
This patent is US-specific. Equivalent patents may exist elsewhere, following similar claims.
5. What is the strategic significance of this patent?
It secures exclusive rights over a specific chemical class and therapeutic method for nearly 20 years, offering a competitive advantage in the targeted neuropsychiatric market.
References
- U.S. Patent and Trademark Office (USPTO). (2016). Patent No. 9,492,429.
- WIPO. (n.d.). Patent family data for international jurisdictions.
- European Patent Office. (n.d.). Patent application filings in schiziphrenia and depression drug space.
- Medical patents literature review, 2014-2022.
- FDA-approved neuropsychiatric drugs and patent mappings.
